Preparation of monoisotopic silver-109 nanoparticles ( 109 AgNPs) by pulsed fiber laser (PFL) ablation synthesis in solution (LASiS) with the use of a 2D galvoscanner (2D GS) is described. The procedure of covering of custom-made stainless-steel MALDI targets containing studied objects via nebulization is also presented. Examples of application of the new method (PFL-2D GS LASiS and nebulization) in mass spectrometry (MS) analyses and MS imaging (MSI) are shown. These include tests with a nonionic nucleoside and saccharide, ionic amino acids, and also a low-molecular-weight polymer. Fingerprint MS imaging is shown as an example of a fast and simple MSI procedure.

Bladder cancer (BC) is a common urological cancer of high mortality and recurrence rates. Currently, cystoscopy is performed as standard examination for the diagnosis and subsequent monitoring for recurrence of the patients. Frequent expensive and invasive procedures may deterrent patients from regular follow-up screening, therefore it is important to look for new non-invasive methods to aid in the detection of recurrent and/or primary BC. In this study, ultra-high-performance liquid chromatography coupled with ultra-high-resolution mass spectrometry was employed for non-targeted metabolomic profiling of 200 human serum samples to identify biochemical signatures that differentiate BC from non-cancer controls (NCs). Univariate and multivariate statistical analyses with external validation revealed twenty-seven metabolites that differentiate between BC patients from NCs. Abundances of these metabolites displayed statistically significant differences in two independent training and validation sets. Twenty-three serum metabolites were also found to be distinguishing between low- and high-grade of BC patients and controls. Thirty-seven serum metabolites were found to differentiate between different stages of BC. The results suggest that measurement of serum metabolites may provide more facile and less invasive diagnostic methodology for detection of bladder cancer and recurrent disease management.

No abstract

A comparison of ionization efficiency for gold and silver nanoparticles used as an active media of matrix-less laser desorption/ionization (LDI) mass spectrometry (MS) methods was made for carboxylic acids including fatty acids. The matrix-assisted laser desorption/ionization (MALDI)-type targets containing monoisotopic cationic 109 Ag nanoparticles (109 AgNPs) and Au nanoparticles (AuNPs) were used for rapid MS measurements of 10 carboxylic acids of different chemical properties. Carboxylic acids were directly quantified in experiments with 10 000-fold concentration change conditions ranging from 1 mg/ml to 100 ng/ml which equates to 1 μg to 100 pg of carboxylic acids per measurement spot.

No abstract

This study aimed to detect and quantify mycotoxins on building materials using innovative laser mass spectroscopy methods—silver-109/silver/gold nanoparticle-enhanced target surface-assisted laser desorption/ionisation mass spectrometry (109AgNPs, AgNPs and AuNPs SALDI). Results from SALDI-type methods were also compared with commonly used matrix-assisted laser desorption/ionization (MALDI) mass spectrometry. Standards of seven moulds mycotoxin in a final concentration of 100 µg/mL for patulin, citrinin, 3-nitropropionic acid, alternariol and 20 µg/mL for sterigmatocystin, cyclopiazonic acid, roquefortine C in the mixture were tested in pure solutions and after extraction from the plasterboards. Among the studied SALDI-type method, the lowest detection limits and the highest signal intensity of the mycotoxins tested were obtained with the use of 109AgNPs SALDI MS. The 109AgNPs method may be considered as an alternative to the currently most frequently used method MALDI MS and also liquid chromatography tandem mass spectrometry LC-MS/MS for mycotoxin determination. Future studies should attempt to use these methods for mass spectrometry imaging (MSI) to evaluate spatial distribution and depth of mycotoxin penetration into building materials.

No abstract

Bladder cancer (BC) is a common urological malignancy with a high probability of death and recurrence. Cystoscopy is used as a routine examination for diagnosis and following patient monitoring for recurrence. Repeated costly and intrusive treatments may discourage patients from having frequent follow-up screenings. Hence, exploring novel non-invasive ways to help identify recurrent and/or primary BC is critical. In this work, 200 human urine samples were profiled using ultra-high-performance liquid chromatography and ultra-high-resolution mass spectrometry (UHPLC-UHRMS) to uncover molecular markers differentiating BC from non-cancer controls (NCs). Univariate and multivariate statistical analyses with external validation identified metabolites that distinguish BC patients from NCs disease. More detailed divisions for the stage, grade, age, and gender are also discussed. Findings indicate that monitoring urine metabolites may provide a non-invasive and more straightforward diagnostic method for identifying BC and treating recurrent diseases.